Chemomab Therapeutics is a clinical-stage biotech developing treatments for rare fibrotic and inflammatory diseases. The company has a single pipeline asset: nebokitug, a humanized monoclonal antibody that blocks CCL24, a protein that drives both inflammation and fibrosis. Nebokitug's lead indication is primary sclerosing cholangitis (PSC), a rare, progressive liver disease that destroys the bile ducts and has no FDA-approved disease-modifying treatments. The secondary indication is systemic sclerosis (SSc), a rare autoimmune disease causing widespread fibrosis of the skin and organs, which also lacks approved disease-modifying therapies. Both indications carry orphan drug designations from the FDA and EMA, providing seven years of marketing exclusivity upon approval. Chemomab completed a Phase 2 trial in PSC in 2024, reporting positive results on safety, liver stiffness, and fibrosis biomarkers, and has since aligned with the FDA on a Phase 3 design targeting roughly 350 patients. The SSc program has been deprioritized while the company focuses on PSC. Chemomab is pre-revenue, funded by equity, and its path to commercialization runs through regulatory approval of nebokitug, after which the company plans to sell either independently or via a licensing or co-commercialization deal with a larger pharma partner. Chemomab operates with a lean team of 12 employees and consultants.